Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression (NCT05784428)
Single vs. Multiple Fraction Non-Inferiority Trial of Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligo-metastases/Progression: SIMPLIFY-SABR-COMET
🩺 Plain-English Summary (8th-Grade Level)
Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques, while trying to avoid healthy tissues and organs. However, SABR treatment requires increased planning, treatment time, cost and potential for higher toxicity due to the higher dose. The purpose of this study is to compare single fraction (SF) SABR vs. multiple fraction (MF) SABR in regards to toxicities, progression-free survival, quality of life (QoL), and cost-effectiveness. In a subset of patients, we will also compare patient QoL, hospitalization rates, and cost-effectiveness between patients who complete QoL questionnaires, record symptoms and receive healthcare provider-guided intervention vs. patients who complete QoL questionnaires only.
Who can join: Review the eligibility criteria below.
Location: BC Cancer — Kelowna, British Columbia
Age range: 18 Years
🧪 Interventions in This Study
- Single fraction SABR (RADIATION)
- Multiple fraction SABR (RADIATION)
- QoL reporting alone (OTHER)
- QoL reporting, symptom screen and healthcare provider intervention (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- BC Cancer — Kelowna, British Columbia
- BC Cancer — Prince George, British Columbia
- BC Cancer — Surrey, British Columbia
- BC Cancer — Vancouver, British Columbia
- BC Cancer - Victoria — Victoria, British Columbia
- Health Sciences North Research Institute — Greater Sudbury, Ontario
- Princess Margaret Cancer Centre | University Health Network — Toronto, Ontario
- University Hospital Galway — Galway, Connacht
- St. Luke's Radiation Oncology Network — Dublin, Dublin
- Mater Private Hospital — Dublin, Leinster
- Beacon Hospital — Dublin, Leinster
- Cork University Hospital — Cork, Munster
- Bon Secours Radiotherapy Cork in Partnership with UPMC Hillman Cancer Centre — Cork, Munster
- UPMC Whitfield Hospital - Waterford — Waterford, Munster
📞 Contact the Study Coordinator
Phone: (250) 645-7300
Email: rolson2@bccancer.bc.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Oligometastatic Disease
Explore by condition: All Oligometastatic Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.